Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

513
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
513
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

438
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
438
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

654
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
654
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.2K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychiatric Comorbidity in Hidradenitis Suppurativa-A Large-Scale Retrospective Cohort Study.

Journal of clinical medicine·2026
Same author

Life with Pain Revalued-A Therapist-Led Support Group for Patients with Chronic Non-Cancer Pain: A Pilot Feasibility Study.

Journal of clinical medicine·2026
Same author

Association Between Bimekizumab's Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II.

Dermatology and therapy·2026
Same author

Position Statement of the EADV Task Forces With External Experts on Quality of Life Measurement in Hidradenitis Suppurativa: An Update.

International journal of dermatology·2026
Same author

Cutaneous Pain in Atopic Dermatitis: Mental Health Burden.

Journal of clinical medicine·2026
Same author

The Skin-Brain-Exposome Axis in Stress-Sensitive Dermatoses: A Narrative Review.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Dec 16, 2025

Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors
04:59

Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors

Published on: September 27, 2019

12.8K

Emerging Therapeutic Options for Chronic Pruritus.

Radomir Reszke1, Piotr Krajewski1, Jacek C Szepietowski2

  • 1Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, 1 Chalubinskiego Street, 50-368, Wrocław, Poland.

American Journal of Clinical Dermatology
|July 2, 2020
PubMed
Summary

Chronic pruritus, lasting over six weeks, presents a significant therapeutic challenge. This review explores emerging treatments like opioidergic drugs and Janus kinase inhibitors for better itch relief.

More Related Videos

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation
08:02

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation

Published on: March 24, 2023

4.6K
Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

9.9K

Related Experiment Videos

Last Updated: Dec 16, 2025

Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors
04:59

Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors

Published on: September 27, 2019

12.8K
A Mouse Ear Model for Allergic Contact Dermatitis Evaluation
08:02

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation

Published on: March 24, 2023

4.6K
Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

9.9K

Area of Science:

  • Dermatology
  • Pharmacology

Background:

  • Chronic pruritus is a widespread, distressing symptom linked to skin and systemic diseases.
  • Current treatments like topical therapies, phototherapy, and systemic drugs offer limited relief due to complex causes.
  • Novel therapeutic strategies are needed for effective chronic itch management.

Purpose of the Study:

  • To review emerging and investigational therapeutic modalities for chronic pruritus.
  • To highlight treatments with potential for near-future approval and improved patient outcomes.

Main Methods:

  • Literature review of current experimental and clinical data on novel antipruritic agents.
  • Focus on pharmacologic interventions currently under investigation.

Main Results:

  • Several novel drug classes show promise, including opioidergic drugs (mu-opioid antagonists, kappa-opioid agonists), neurokinin-1 receptor antagonists, biologic drugs, Janus kinase inhibitors, ileal bile acid transporter inhibitors, aryl hydrocarbon receptor agonists, and histamine H4 receptor antagonists.
  • These agents target diverse pathways implicated in chronic pruritus pathogenesis.

Conclusions:

  • Emerging therapies offer new hope for managing chronic pruritus, addressing limitations of existing treatments.
  • Further research and clinical trials are essential to validate these promising novel treatments for widespread use.